BioCryst Pharmaceuticals, Inc. (BCRX)

NASDAQ: BCRX · Real-Time Price · USD
9.91
-0.19 (-1.88%)
At close: Jun 23, 2025, 4:00 PM
9.99
+0.08 (0.81%)
After-hours: Jun 23, 2025, 7:54 PM EDT
-1.88%
Market Cap 2.07B
Revenue (ttm) 503.49M
Net Income (ttm) -53.47M
Shares Out 209.25M
EPS (ttm) -0.26
PE Ratio n/a
Forward PE 33.55
Dividend n/a
Ex-Dividend Date n/a
Volume 2,690,448
Open 10.02
Previous Close 10.10
Day's Range 9.72 - 10.04
52-Week Range 6.00 - 11.31
Beta 1.10
Analysts Buy
Price Target 16.75 (+69.02%)
Earnings Date Aug 4, 2025

About BCRX

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhib... [Read more]

Sector Healthcare
IPO Date Mar 3, 1994
Employees 580
Stock Exchange NASDAQ
Ticker Symbol BCRX
Full Company Profile

Financial Performance

In 2024, BioCryst Pharmaceuticals's revenue was $450.71 million, an increase of 36.00% compared to the previous year's $331.41 million. Losses were -$88.88 million, -60.77% less than in 2023.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for BCRX stock is "Buy." The 12-month stock price forecast is $16.75, which is an increase of 69.02% from the latest price.

Price Target
$16.75
(69.02% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

—Data across pediatric, adolescent, and adult populations demonstrate sustained reductions in HAE attacks and consistent safety profile—

7 days ago - GlobeNewsWire

ORLADEYO® (berotralstat) Approved in Colombia

RESEARCH TRIANGLE PARK, N.C., June 13, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National Institute of Drug and Food Surveillance (INVIMA) in Colo...

10 days ago - GlobeNewsWire

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland...

17 days ago - GlobeNewsWire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted s...

20 days ago - GlobeNewsWire

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

RESEARCH TRIANGLE PARK, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophyl...

21 days ago - GlobeNewsWire

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of life New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supp...

24 days ago - GlobeNewsWire

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:

27 days ago - GlobeNewsWire

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

RESEARCH TRIANGLE PARK, N.C., May 16, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotrals...

5 weeks ago - GlobeNewsWire

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

–FDA grants Priority Review of application, with PDUFA target action date of September 12, 2025– – ORLADEYO would be the first targeted oral prophylactic therapy for patients with HAE under the age of...

5 weeks ago - GlobeNewsWire

BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

BioCryst Pharmaceuticals, Inc. BCRX on Monday reported first-quarter sales of $145.50 million, up 52.7% year over year, beating the consensus of $126.87 million.

7 weeks ago - Benzinga

BioCryst: Strong Opportunity For A Double With A Proven Therapy

BioCryst Pharmaceuticals' flagship product ORLADEYO shows remarkable growth, maintaining a persistent upward trajectory since its launch in 2020, and is expected to continue into 2025. Despite heavy r...

7 weeks ago - Seeking Alpha

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer ...

7 weeks ago - Seeking Alpha

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

—Q1 2025 ORLADEYO net revenue of $134.2 million (+51 percent y-o-y)— —Full year 2025 ORLADEYO revenue guidance increased to $580 million to $600 million— —Company now expects to be profitable for full...

7 weeks ago - GlobeNewsWire

BioCryst Appoints Steve Frank to Board of Directors

RESEARCH TRIANGLE PARK, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed healthcare investment banking leader Steve Fr...

7 weeks ago - GlobeNewsWire

BioCryst to Report First Quarter 2025 Financial Results on May 5

RESEARCH TRIANGLE PARK, N.C., April 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2025 financial results on ...

2 months ago - GlobeNewsWire

BioCryst to Present at Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., April 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 24th Annual Needham Virtual Heal...

2 months ago - GlobeNewsWire

BioCryst: Orladeyo's Expansion Is Just Getting Started

BioCryst Pharmaceuticals, a rare disease biotech, shows strong revenue growth from ORLADEYO, a healthy cash position, and a promising pipeline, making it an attractive investment. Despite a net loss, ...

4 months ago - Seeking Alpha

BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up

BioCryst Pharmaceuticals stock rose 9% since September, driven by strong Orladeyo sales and raised revenue guidance for 2025 to $535-$550 million. Orladeyo's convenience over injectable therapies is s...

4 months ago - Seeking Alpha

BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical

I initially rated BioCryst a "Sell" in November 2023, but am now upgrading to "Hold" as the company has outperformed my expectations, despite competitive pressures. Orladeyo, BioCryst's main revenue s...

4 months ago - Seeking Alpha

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2024 Earnings Call Transcript

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2024 Earnings Conference Call February 24, 2025 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie ...

4 months ago - Seeking Alpha

BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings

On Monday, BioCryst Pharmaceuticals, Inc.  BCRX released results from an interim analysis of the ongoing APeX-P trial.

4 months ago - Benzinga

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

—ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)—

4 months ago - GlobeNewsWire

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to

– Additional real-world studies with ORLADEYO show statistically significant HAE attack rate reductions experienced by patients with C1-INH deficiency and normal C1-INH levels and function –

4 months ago - GlobeNewsWire

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Infarmed in Portugal has recommended ORLADEYO® (berotralstat) for the...

4 months ago - GlobeNewsWire

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts featuring new clinical and re...

4 months ago - GlobeNewsWire